Wells Fargo’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-50,000
Closed -$4.15M 7431
2025
Q2
$4.15M Buy
+50,000
New +$3.99M ﹤0.01% 2623
2025
Q1
Sell
-405,100
Closed -$36.5M 7303
2024
Q4
$36.5M Buy
405,100
+300,100
+286% +$29.1M 0.01% 972
2024
Q3
$10.4M Hold
105,000
﹤0.01% 1805
2024
Q2
$9.73M Hold
105,000
﹤0.01% 1757
2024
Q1
$9.96M Buy
+105,000
New +$9.74M ﹤0.01% 1743
2023
Q1
Sell
-60,000
Closed -$4.98M 7818
2022
Q4
$4.98M Buy
60,000
+35,000
+140% +$2.83M ﹤0.01% 2085
2022
Q3
$1.98M Buy
+25,000
New +$2.11M ﹤0.01% 2747
2022
Q2
Sell
-25,000
Closed -$2.25M 7606
2022
Q1
$2.25M Buy
+25,000
New +$2.31M ﹤0.01% 3189
2021
Q2
Sell
-107,100
Closed -$14.5M 7528
2021
Q1
$14.5M Buy
+107,100
New +$16M ﹤0.01% 1908
2018
Q3
Sell
-142,000
Closed -$136K 6611
2018
Q2
$136K Buy
142,000
+103,000
+264% +$9.47M ﹤0.01% 5227
2018
Q1
$8K Buy
+39,000
New +$3.56M ﹤0.01% 5989

Other funds holding XBI

Wells Fargo's XBI Position: Q1 2026 in Review

Wells Fargo reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 23% in Q1 2026, selling an estimated $102M and leaving 2,746,209 shares worth $351M. The position accounts for 0.07% of the portfolio, ranked #257.

Wells Fargo first reported a position in XBI in Q2 2013 and has held it in 52 quarters since. The position peaked at $435M in Q4 2025. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Wells Fargo held 2,746,209 shares of State Street SPDR S&P Biotech ETF worth $351M as of Q1 2026.
  • Wells Fargo sold 820,056 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $102M.
  • State Street SPDR S&P Biotech ETF made up 0.07% of Wells Fargo's portfolio in Q1 2026, its #257 holding.
  • Wells Fargo first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 52 quarters since.
  • Wells Fargo's State Street SPDR S&P Biotech ETF position peaked at $435M in Q4 2025.
  • 814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.